NCT06897605

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

Conditions

• Chronic Kidney Disease(CKD)
• Anemia, Kidney Disease, Chronic

Interventions

Type	Name	Description
DRUG	Dapagliflozin (DAPA)	Dapagliflizin 10 mg tablets once daily for 12 weeks
DRUG	Erythropoiesis Stimulating Agent	Erythropoiesis stimulating agent (ESA) therapy

Timeline

• Start date: 2025-04-01
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2025-03-27
• Last updated: 2025-04-02

Locations

1 site across 1 country: Egypt